Chidamide: Clinical Trials

30 trials of Chidamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 unknown, 6 completed, 5 not yet recruiting, 5 recruiting. 30 Phase 1, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 130Unknown 10, Completed 6, Not yet recruiting 5, Recruiting 5, Terminated 3, Active not recruiting 1
Phase 225Unknown 10, Not yet recruiting 5, Completed 4, Recruiting 4, Active not recruiting 1, Terminated 1

Follow Chidamide: new trials by email Literature Review of Chidamide trials Research Report on Chidamide

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Lisaftoclax, Chidamide, rituximab - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University512026-05-302026-05-22
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
Chidamide, radiotherapy - Head and Neck Squamous Cell Carcinoma HNSCC
Phase 1RecruitingWest China Hospital62026-04-232026-04-28
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
Polatuzumab Vedotin, Rituximab (R), Chidamide - Double Expressor DLBCL
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University682026-04-012026-02-17
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Chidamide, Toripalimab, Anlotinib - Nasopharyngeal Carcinoma
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University522026-03-312026-03-20
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Zeprumetostat, Golidocitinib, Chidamide - Mature T-cell and NK-cell Lymphoma
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University602026-01-012026-01-14
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Linperlisib, Chidamide - Peripheral T Cells Lymphoma (PTCL)
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University542025-09-152025-08-24
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma
Phase 1 / Phase 2RecruitingSun Yat-sen University1012025-08-272025-12-31
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
golidocitinib, Chidamide - Cutaneous T-cell Lymphoma (CTCL)
Phase 1 / Phase 2RecruitingPeking Union Medical College Hospital652025-08-262026-08-12
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia
Phase 1 / Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China422023-10-302023-11-02
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Chidamide, Regorafenib - Hepatocellular Carcinoma (HCC)
Phase 1 / Phase 2TerminatedGreat Novel Therapeutics Biotech & Medicals Corporation72023-04-252025-03-11
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Chidamide - Leukemia, Myeloid, Acute
Phase 1 / Phase 2RecruitingSichuan University772022-12-222023-01-12
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
Chidamide - Breast Cancer, Chemotherapy Effect
Phase 1 / Phase 2UnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences402022-11-012023-02-28
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Dalpiciclib, Chidamide - HR+/HER2- Advanced Breast Cancer
Phase 1CompletedBeijing 302 Hospital222022-10-012026-05-29
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
chidamide, celecoxib - Metastatic Colorectal Cancer
Phase 1TerminatedTaipei Medical University Shuang Ho Hospital92022-09-202024-12-20
Chidamide in Combination With Abemaciclib and Endocrinotherapy(Doctor's Choice) in Breast Cancer Patients Previously Treated With Palbociclib
Chidamide, Abemaciclib, endocrinotherapy(doctor's choice) - Breast Cancer
Phase 1 / Phase 2UnknownBiyun Wang, MD442022-07-012024-01-22
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
APG-1252, Chidamide - NHL, Adult
Phase 1 / Phase 2UnknownAscentage Pharma Group Inc.512022-06-142024-01-23
Chidamide Bridging for CAR-T Therapy
Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma
Phase 1 / Phase 2UnknownChinese PLA General Hospital1202022-05-252024-03-06
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
Chidamide, Decitabine, Immune checkpoint inhibitors(anti-PD1/PD-L1/CTLA4 antibodies) - Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors
Phase 1 / Phase 2UnknownChinese PLA General Hospital1002022-03-302022-04-11
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma
Phase 1TerminatedHenan Cancer Hospital122022-02-202025-12-02
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Azacitidine, Chidamide - Leukemia, Myeloid, Acute
Phase 1 / Phase 2RecruitingZhujiang Hospital402022-02-012026-07-07

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Lymphoma, Non-Hodgkin (5)  ·  Lymphoma, T-Cell, Peripheral (3)  ·  Breast Neoplasms (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma, T-Cell (2)  ·  Recurrence (2)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Thrombocytopenia (1)

Sponsors

Sun Yat-sen University (6)  ·  Chinese PLA General Hospital (4)  ·  Chipscreen Biosciences, Ltd. (2)  ·  Institute of Hematology & Blood Diseases Hospital, China (2)  ·  Peking Union Medical College Hospital (2)  ·  Ascentage Pharma Group Inc. (1)  ·  Beijing 302 Hospital (1)  ·  Biyun Wang, MD (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Great Novel Therapeutics Biotech & Medicals Corporation (1)  ·  Henan Cancer Hospital (1)  ·  Huiqiang Huang (1)  ·  Shandong University (1)  ·  Sichuan University (1)  ·  Taipei Medical University Shuang Ho Hospital (1)

Countries

China (23)  ·  Taiwan (2)

Top investigators

Binghe Xu (1)  ·  Biyun Wang (1)  ·  Chia-Nan Chen, Ph.D. (1)  ·  Daobin Zhou, M.D (1)  ·  Jianxiang Wang, Dr (1)  ·  Rui Huang, Doctor (1)  ·  Weidong Han, M.D. (1)  ·  Weidong Han, Ph.D (1)  ·  Weidong Han, Prfessor (1)  ·  Xingchen Peng (1)  ·  Yanyan Liu, M.D. Ph.D (1)  ·  Yifan Zhai, MD, PhD (1)  ·  Yongtao Sun, M.D., Ph.D. (1)  ·  Yuankai Shi, MD (1)

Results publications

PMID 30209556, PMID 38805037, PMID 42827632